Sort
4,870 grants matching “glp 1”
Glucagon-mediated glycemic effect in humans with and without rerouted gut after bariatric surgery
$775,865Marzieh Salehi · University Of Texas Hlth Science Center · R01 · FY2025 · DK
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur
$774,459Garry John Southan · Radikal Therapeutics, Inc. · U01 · FY2014 · ES
Advancing the small molecule drug candidate with dual specificity as a therapy for dry AMD
$774,169Konstantin Petrukhin · Columbia University Health Sciences · R61 · FY2024 · EY
Development of KCC2 neuromodulators to treat paralysis after spinal cord injury.
$773,769Joanna Stanicka · Axonis Therapeutics, Inc. · R44 · FY2022 · NS
Development and Pre-Clinical Trial Qualification of a Pediatric Pump-Lung System for Children
$773,727Bartley Perry Griffith · University Of Maryland Baltimore · R01 · FY2020 · HL
HashtagHealth
$772,963Quynh Nguyen · National Institute Of Nursing Research · ZIA · FY2025 · NR
Prior Glucagon-like Peptide-1 Receptor Agonist Therapy and Pregnancy, Postpartum, and Child Cardiovascular Outcomes: A Target Trial
$772,581Sadiya Sana Khan · Northwestern University At Chicago · R01 · FY2025 · HL
Novel approaches to improve comparative effectiveness research of medical and surgical weight reduction strategies in clinical practice
$772,572Elisabetta Patorno · Brigham And Women'S Hospital · R01 · FY2025 · DK
"NextGen Long-acting Platform: Targeted Combination Antiretrovirals"
$771,303Ann Cornwall Collier · University Of Washington · U01 · FY2020 · AI
Topical Eyedrop Therapy for Keratoconus
$771,002Sarah Abdulla Molokhia · Iveena Delivery Systems, Inc. · R44 · FY2020 · EY
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent For Diagnosis of Renal Failure
$770,967Balaji Sitharaman · Theragnostic Technologies, Inc. · R44 · FY2015 · DK
Nrf2 and the expansion and preservation of beta cell mass
$770,308Donald K Scott · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · DK
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy
$769,710Grace A McComsey · Case Western Reserve University · R01 · FY2020 · DK
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events
$768,622James Blackledge · Capella Imaging, Llc · R42 · FY2018 · HL
Core--Development and analysis of SOD/Catalase mimetics
$768,513Susan Doctrow · Medical College Of Wisconsin · U19 · FY2008 · AI
DEVELOPING MULTI-ANTIGEN VACCINE FOR THE TREATMENT OF CHRONIC HBV
$768,496Valerian Nakaar · Carogen Corporation · R44 · FY2020 · DK
Pathogenesis of youth onset pre-diabetes and Type 2 diabetes
$768,468Sonia Caprio · Yale University · R01 · FY2021 · DK
Long-acting EPO analog for treating anemia associated with chronic kidney disease
$767,785George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2009 · DK
Biobehavioral Studies of Obesity, Weight loss and Recidivism
$767,008Ranganath Muniyappa · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
$766,731Charles Testa · Curza Inc · R01 · FY2018 · AI
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels
$766,685Fernando Aleman Guillen · Navega Therapeutics, Inc. · R44 · FY2021 · CA
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
$766,596John N Van Den Anker · Children'S Research Institute · U54 · FY2013 · HD
Developing robust anti-Obesity Medication ImplemeNtatiOn approaches to maximize population health (the DOMINO study)
$766,551Matthew L Maciejewski · Duke University · R01 · FY2024 · DK
Pathogenesis of youth onset pre-diabetes and Type 2 diabetes
$766,354Sonia Caprio · Yale University · R01 · FY2022 · DK
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy
$766,113Grace A McComsey · Case Western Reserve University · R01 · FY2021 · DK